ArticleJCO precision oncology2021
Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma.
Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation.Oncogene · 2026Review
- Efficacy and safety of durvalumab plus gemcitabine-cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma.ESMO open · 2026Article
- Single-cell transcriptomic mapping of patient-derived primary liver cancer organoids reveals molecular subtypes and guides precision drug targeting.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Surgical management of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a narrative review of principles, technical nuances, and emerging strategies.Journal of liver cancer · 2026Review
- Systemic therapy for combined hepatocellular-cholangiocarcinoma: a comprehensive review of chemotherapy, immunotherapy, and targeted therapy.Journal of liver cancer · 2026Review
- Combined hepatocellular-cholangiocarcinoma: a contemporary pathologic and molecular perspective.Journal of liver cancer · 2026Review
- Systemic treatment strategies for combined hepatocellular-cholangiocarcinoma: current evidence and future direction.Journal of liver cancer · 2026Review
- Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions.Frontiers in oncology · 2026Review
- Edge learning applications in the prediction and classification of combined hepatocellular-cholangiocarcinoma: A comprehensive narrative review.World journal of clinical oncology · 2025Review
- Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma.Frontiers in oncology · 2025Article
- Persistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion.Molecular cancer · 2024Article
- A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors.Briefings in bioinformatics · 2024Article
- Syngeneic mouse model of YES-driven metastatic and proliferative hepatocellular carcinoma.Disease models & mechanisms · 2024Article
- Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study.Virchows Archiv : an international journal of pathology · 2024Article
- Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.United European gastroenterology journal · 2024Article
- Application of AI on cholangiocarcinoma.Frontiers in oncology · 2024Review
- Article
- Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma.Cancers · 2023Review
- Etiology, Pathogenesis, Diagnosis, and Practical Implications of Hepatocellular Neoplasms.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCombined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare, aggressive primary liver carcinoma, with morphologic features of both hepatocellular carcinomas (HCC) and liver cholangiocarcinomas (CCA).
methodsThe genomic profiles of 4,975 CCA, 1,470 HCC, and 73 cHCC-CCA cases arising from comprehensive genomic profiling in the course of clinical care were reviewed for genomic alterations (GA), tumor mutational burden, microsatellite instability status, genomic loss of heterozygosity, chromosomal aneuploidy, genomic ancestry, and hepatitis B virus status.
resultsIn cHCC-CCA, GA were most common in
conclusionThese findings demonstrate the use of ML for classification as based on a targeted exome panel used during routine clinical care. Classification of cHCC-CCA by genomic features alone creates insights into the biology of the disease and warrants further investigation for relevance to clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.